<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543827</url>
  </required_header>
  <id_info>
    <org_study_id>MV140-SLG-003</org_study_id>
    <secondary_id>2013-001838-17</secondary_id>
    <nct_id>NCT02543827</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of MV140</brief_title>
  <acronym>MV140</acronym>
  <official_title>Prospective Randomized, Double-blind, Parallel-controlled Versus Placebo in a Polyvalent Sublingual Bacterial Vaccine to 3 Months and 6 Months in Women With RUTI for the Immunomodulatory Efficacy Evaluation, Safety and Clinical Impact</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of a biological vaccine
      (MV140) in women with Recurrent Urinary Tract Infections (RUTI) compared with a placebo
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind parallel placebo controlled study. The subjects will receive medication during
      three or six months and will be followed up during another twelve months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in the number of RUTI exacerbations.</measure>
    <time_frame>1 year</time_frame>
    <description>Average reduction of RUTI exacerbations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of RUTI exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Review of RUTI exacerbations episodes severity per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First RUTI exacerbation</measure>
    <time_frame>1 year</time_frame>
    <description>When takes place the First RUTI exacerbation for every single patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication consumption</measure>
    <time_frame>1 year</time_frame>
    <description>Review of medication consumed from the beginning to the end of the RUTI exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health resource consumption</measure>
    <time_frame>1 year</time_frame>
    <description>Counting the Health resource consumption due to RUTI exacerbation: visits to specialists, telephone calls, analyzes and urocultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the emergency service</measure>
    <time_frame>1 year</time_frame>
    <description>Counting the number of visits to the emergency service due to RUTI exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations due to RUTI exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Counting the number of hospitalization days due to RUTI exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in RUTI Assessment Test</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the RUTI Assessment Test results at the beginning and at the end of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of difference in immunological parameters from baseline to end of the trial</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the changes from specific cell proliferation baseline against antigens of the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>Review of the number of adverse event per patient</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Urinary Tract Infection Bacterial</condition>
  <arm_group>
    <arm_group_label>MV140 I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive daily dose of MV140 during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MV140 II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will receive daily dose of placebo during 6 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MV140</intervention_name>
    <description>The subjects will receive daily dose of MV140 during 3 or 6 months</description>
    <arm_group_label>MV140 I</arm_group_label>
    <arm_group_label>MV140 II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The subjects will receive daily dose of placebo during 3 or 6 months</description>
    <arm_group_label>MV140 II</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gave written informed consent.

          -  Women

          -  Aged between 18 and 75 years.

          -  They must be able to meet the dosing regimen.

          -  Individuals who have had at least 3 episodes of cystitis in the past 12 months.

          -  Subject that does not have responded to health and hygiene measures and/or suppressive
             treatments and/or postcoital prophylaxis.

        Exclusion Criteria:

          -  Not have granted the informed written consent.

          -  Not included in the established age range.

          -  Not to offer cooperation I have serious psychiatric disorders.

          -  Present pathological post-voiding residue.

          -  Submit moderada-grave incontinence.

          -  Present genital tumors.

          -  Suffering from urinary tract tumors.

          -  Submit lithiasis.

          -  Present alterations in the immune system.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernanda Lorenzo, PhD; MD-prof</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_official>
    <last_name>Isidoro Martín, PhD; MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Sánchez, PhD; MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Manuel José Vicente, PhD; MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Stephen Foley, FRCS (Urol)</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Fernanda Lorenzo, PhD; MD</last_name>
    <phone>+34923 294 400</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel Casanovas, PhD; MD</last_name>
    <phone>3434916510010</phone>
    <email>mcasanovas@inmunotek.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Salud Universidad Centro</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y LEÓN</state>
        <zip>37001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isidoro Martín, MD</last_name>
      <phone>+34923 21 99 11</phone>
    </contact>
    <investigator>
      <last_name>Isidoro Martín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Capuchinos</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y LEÓN</state>
        <zip>37006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel José Vicente, MD</last_name>
      <phone>+34923 20 51 00</phone>
    </contact>
    <investigator>
      <last_name>Manuel José Vicente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y LEÓN</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Lorenzo, MD</last_name>
      <phone>+34923 294 400</phone>
    </contact>
    <investigator>
      <last_name>Fernanda Lorenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENTRO DE SALUD de PEÑARANDA</name>
      <address>
        <city>Peñaranda de Bracamonte</city>
        <state>Salamanca, Castilla Y LEÓN</state>
        <zip>37300</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Sánchez, MD</last_name>
      <phone>+34923 54 16 00</phone>
    </contact>
    <investigator>
      <last_name>Alfonso Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital Nhs Foundation Trust</name>
      <address>
        <city>Reading</city>
        <state>London</state>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Foley, MBBS, FRCS</last_name>
      <phone>+441183228692</phone>
    </contact>
    <investigator>
      <last_name>Stephen Foley, MBBS, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Recurrent Urinary Tract Infections (RUTI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

